Kalshi Is Seeking a $40 Billion Valuation — Seven Weeks After Raising at $22 Billion
Kalshi is in talks for a new funding round at a $40 billion valuation, nearly doubling the $22 billion figure from its May 2026 Series F, according to the Financial Times. The company's annualized revenue has crossed $2 billion, and CEO Tarek Mansour confirmed the company is in early IPO discussions — though a listing will not happen before 2027. Combined Kalshi and Polymarket volume hit $44.8 billion in June, a 75% jump from May.
Kalshi is seeking a new round of outside investment at a valuation of approximately $40 billion, according to the Financial Times, just seven weeks after closing a $1 billion Series F at a $22 billion valuation. The funding round talks come alongside a public disclosure of the company's revenue trajectory: annualized revenue has crossed $2 billion, versus approximately $1 billion for Polymarket. The valuation climb tells the story of the year in compressed form: Kalshi was worth around $2 billion in June 2025, $11 billion by December, $22 billion in May 2026, and is now targeting $40 billion. The investors from the Series F — Coatue, Sequoia, Andreessen Horowitz, and Morgan Stanley — have seen their stake roughly double in value in under two months.
CEO Tarek Mansour confirmed to CNBC that the company is in early conversations about an eventual IPO but said emphatically that a public offering will not happen in 2026. Reports suggest late 2027 or 2028 as the realistic window, pending market conditions. The IPO discussion is itself a milestone: Kalshi's entire existence until this year was a regulatory fight to establish that its products were legal. That fight is not over — nine states are in active litigation — but the company is now simultaneously defending its right to operate in court and planning what a public offering might look like. Those two things coexist because the CFTC's legal posture strongly suggests the federal-preemption arguments will ultimately hold.
The combined Kalshi and Polymarket monthly trading volume for June was $44.8 billion, a 75% surge from May's $25.66 billion — driven overwhelmingly by World Cup trading. Kalshi claims more than 90% of US prediction market activity by volume. Institutional trading volume grew 800% in the six months ended June 2026. These are not the numbers of a niche product: they are approaching the scale of mid-tier US futures exchanges, which is precisely the comparison Kalshi wants analysts and potential IPO investors to make. The CFTC's proposed rule — open for public comment until July 27 — would formalize the regulatory regime that underpins all of it, converting the agency's litigation posture into codified regulation.
The $40 billion target is also a statement about competitive positioning. Polymarket reached $1 billion in annualized revenue six weeks after its US launch, which is extraordinary growth — but it is half of Kalshi's current figure. Bernstein analysts noted in a June 29 report that Kalshi owns the exchange stack and has built federally regulated infrastructure, but that it 'trails on distribution,' leaving it plausibly a target as well as an acquirer. The report named Robinhood, Coinbase, and DraftKings as potential acquirers. Mansour's IPO positioning is a direct response to that framing: a $40 billion public valuation makes a friendly acquisition harder to execute and establishes Kalshi as a standalone financial exchange rather than an asset to be absorbed into a larger consumer platform.
Operators mentioned in this article
Recent updates
Prediction Markets Hit Wall Street Earnings Season: DraftKings at $11B Annualized Volume, Robinhood at $156M Revenue, Coinbase at $100M+
Prediction markets featured prominently in Q2 2026 earnings reports from DraftKings, Robinhood, Coinbase, and Flutter. DraftKings' prediction platform grew from $2.3 billion to $11 billion in annualized volume between April and July, with CEO Jason Robins expecting 'millions' of users by NFL season. Robinhood's Rothera generated $156 million in event contracts revenue in its first partial quarter. Coinbase reported 106% quarter-over-quarter growth in prediction market revenue, surpassing $100 million annualized. Flutter is moving FanDuel Predicts from CME to Crypto.com ahead of the NFL season.
Kalshi and Polymarket Are Now Taking Bets on Clinical Trials. Researchers Say That Is a Structural Integrity Problem.
Kalshi and Polymarket have begun allowing users to bet on the outcomes of clinical drug trials and FDA approval decisions. Researchers running those trials say the markets create direct financial incentives for people with access to trial data — pharmacists, coordinators, investigators — to tamper with results. Kalshi argues the markets are no different from stock market short sellers and will provide valuable information about drug development. Critics call the whole thing 'ghastly.' The debate represents the most ethically serious challenge prediction markets have faced.
Polymarket Becomes the ATP Tour's Official Prediction Market Provider — With Sportradar Supplying Integrity Monitoring
Polymarket has signed a deal with Tennis Data Innovations, the joint venture between the ATP Tour and ATP Media Holdings, to become the tour's official prediction market provider. The agreement covers approximately 20,000 matches per season across the ATP Tour and ATP Challenger Tour, with official live data and odds supplied by Sportradar — which will also provide integrity monitoring services. US users will get integrated live streaming alongside real-time prediction market contracts. It is Polymarket's second major data and streaming partnership in two days, following the Genius Sports deal on August 5.